Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/17843286.2021.1940776 http://scihub22266oqcxt.onion/10.1080/17843286.2021.1940776 34152943!8220433!34152943     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Acta+Clin+Belg 2022 ; 77 (3): 647-652 Nephropedia Template TP {{tp|p=34152943|t=2022. Performance of the FREND COVID-19 IgG/IgM Duo point-of-care test for SARS-CoV-2 antibody detection |pdf=|usr=}}{{34152943}} gab.com Text Performance of the FREND COVID-19 IgG/IgM Duo point-of-care test for SARS-CoV-2 antibody detection JO: Acta Clin Belg http://www.kidney.de/pget.php?&tw=1&pmid=34152943 #FOAvip PURPOSE: In the context of the current COVID-19 pandemic, multiple serological assays for the detection of severe acute respiratory syndrome 2 (SARS-CoV-2) immune response are currently being developed. This study compares the FREND(TM) COVID-19 IgG/IgM Duo (NanoEntec) a point of care (POCT) assay with the automated Elecsys anti-SARS-CoV-2 electrochemiluminescent assay (Roche Diagnostics). METHODS: Serum samples (n = 81) from PCR-confirmed SARS-CoV-2 positive patients at different time points after the onset of symptoms were analyzed with both assays. An additional 24 serum samples with cross reactivity potential were also included. RESULTS: The sensitivity of the COVID-19 IgG/IgM Duo assay was higher as compared to the Elecsys anti-SARS-CoV-2 assay, especially when using the combined IgM/IgG result in samples analyzed within 6 days after the onset of symptoms (46.2% vs. 15.4%). The sensitivity of both assays increased with increasing time interval after the onset of symptoms and reached 100% for the COVID-19 IgG/IgM Duo assay in samples taken 14 days or more after symptom onset. Specificity of the COVID-19 IgG/IgM Duo assay was 95.8% for IgM, 91.7% for IgG and 87.5% for the combination of both. CONCLUSION: This study shows that the sensitivity of both assays was highly dependent on the time interval between the onset of the COVID-19 symptoms and serum sampling. Furthermore, rapid serological testing for SARS-CoV-2 antibodies by means of the FREND(TM) COVID-19 IgG/IgM Duo POCT assay showed a comparable diagnostic performance as the reference automated immunoassay. Twit Text FOAVip Performance of the FREND COVID-19 IgG/IgM Duo point-of-care test for SARS-CoV-2 antibody detection ????Acta Clin Belg http://www.kidney.de/pget.php?&tw=1&pmid=34152943 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34152943 #FOAvip English Wikipedia <ref>{{Cite pmid|34152943}}</ref> Performance of the FREND COVID-19 IgG/IgM Duo point-of-care test for SARS-CoV-2 antibody detection #MMPMID34152943 De Munck DG; Peeters B; Huyghe E; Goossens H; Ieven M; Matheeussen V Acta Clin Belg 2022[Jun]; 77 (3): 647-652 PMID34152943show ga PURPOSE: In the context of the current COVID-19 pandemic, multiple serological assays for the detection of severe acute respiratory syndrome 2 (SARS-CoV-2) immune response are currently being developed. This study compares the FREND(TM) COVID-19 IgG/IgM Duo (NanoEntec) a point of care (POCT) assay with the automated Elecsys anti-SARS-CoV-2 electrochemiluminescent assay (Roche Diagnostics). METHODS: Serum samples (n = 81) from PCR-confirmed SARS-CoV-2 positive patients at different time points after the onset of symptoms were analyzed with both assays. An additional 24 serum samples with cross reactivity potential were also included. RESULTS: The sensitivity of the COVID-19 IgG/IgM Duo assay was higher as compared to the Elecsys anti-SARS-CoV-2 assay, especially when using the combined IgM/IgG result in samples analyzed within 6 days after the onset of symptoms (46.2% vs. 15.4%). The sensitivity of both assays increased with increasing time interval after the onset of symptoms and reached 100% for the COVID-19 IgG/IgM Duo assay in samples taken 14 days or more after symptom onset. Specificity of the COVID-19 IgG/IgM Duo assay was 95.8% for IgM, 91.7% for IgG and 87.5% for the combination of both. CONCLUSION: This study shows that the sensitivity of both assays was highly dependent on the time interval between the onset of the COVID-19 symptoms and serum sampling. Furthermore, rapid serological testing for SARS-CoV-2 antibodies by means of the FREND(TM) COVID-19 IgG/IgM Duo POCT assay showed a comparable diagnostic performance as the reference automated immunoassay. |*COVID-19/diagnosis[MESH] |Antibodies, Viral[MESH] |Humans[MESH] |Immunoassay[MESH] |Immunoglobulin G[MESH] |Immunoglobulin M[MESH] |Pandemics[MESH] |Point-of-Care Testing[MESH] |SARS-CoV-2[MESH]Performance of the FREND COVID-19 IgG/IgM Duo point-of-care test for S(epmc).pdf DeepDyve Pubget Overpricing